Yes, in the sense that.... Section 21.03 of the Patent Act currently refers to schedule 1, the list of drugs, and the process for adding to those drugs on the recommendation of the Minister of Industry and the Minister of Health. Bill C-393 would delete not only schedule 1, but the process for amending that schedule.
So the reference that is in your definition, Mr. Garneau, to “on the recommendation of the Minister of Industry and the Minister of Health”, would not exist under Bill C-393.